|
| 35286385 | HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. | Blood | 2022 |
| 35358434 | Sex specific definitions of anaemia reflect androgen production. | Lancet Haematol | 2022 |
| 34865702 | Advances in polycythemia vera and lessons for acute leukemia. | Best Pract Res Clin Haematol | 2021 |
| 33911177 | Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases? | Leukemia | 2021 |
| 33777803 | The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN. | Front Oncol | 2021 |
| 32479500 | Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. | PLoS One | 2020 |
| 31982040 | Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now? | Lancet Haematol | 2020 |
| 32542392 | Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. | Blood Adv | 2020 |
| 31151982 | How I treat polycythemia vera. | Blood | 2019 |
| 31230732 | Treatment of Iron Deficiency in the Elderly: A New Paradigm. | Clin Geriatr Med | 2019 |
| 31221790 | Mutated <i>CALR</i>: tails from the crypt. | Blood | 2019 |
| 29516275 | Polycythemia Vera. | Curr Treat Options Oncol | 2018 |
| 27916397 | Polycythaemia vera and precision medicine: a prescription for the 21st century. | Lancet Oncol | 2017 |
| 28395806 | Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. | Stem Cell Res | 2017 |
| 28564565 | Myeloproliferative Neoplasms. | N Engl J Med | 2017 |
| 28854086 | Myeloproliferative Neoplasms. | N Engl J Med | 2017 |
| 28543980 | Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. | Am J Hematol | 2017 |
| 24958831 | Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis. | J Clin Oncol | 2016 |
| 27697978 | Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era. | J Natl Compr Canc Netw | 2016 |
| 26043386 | Paroxysmal cold hemoglobinuria. | Hematol Oncol Clin North Am | 2015 |
| 24105986 | Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. | Stem Cells | 2014 |
| 27175268 | The polycythemia vera stem cell. | Leuk Suppl | 2014 |
| 25162887 | Two clinical phenotypes in polycythemia vera. | N Engl J Med | 2014 |
| 23216617 | Polycythemia vera, the hematocrit, and blood-volume physiology. | N Engl J Med | 2013 |
| 23827419 | Polycythaemia vera. | Hematology | 2013 |
| 23599949 | Treatment target in polycythemia vera. | N Engl J Med | 2013 |
| 23392352 | Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera? | Blood Coagul Fibrinolysis | 2013 |
| 23580059 | Update in hematology and oncology: evidence published in 2012. | Ann Intern Med | 2013 |
| 23265742 | MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. | Blood Cells Mol Dis | 2013 |
| 23245211 | Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. | Leuk Lymphoma | 2013 |
| 21983176 | Treatment of polycythemia vera with imatinib mesylate. | Leuk Res | 2012 |
| 20888389 | Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. | Exp Hematol | 2011 |
| 22084670 | Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. | Thrombosis | 2011 |
| 21799102 | The treatment of essential thromobocytosis revisited. | Blood | 2011 |
| 21712540 | Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. | Haematologica | 2011 |
| 21710838 | Iron and the anemia of chronic disease: vindication for the non-essential role of iron supplementation. | Oncology (Williston Park) | 2011 |
| 21417854 | Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. | Expert Rev Anticancer Ther | 2011 |
| 20378759 | An inconvenient truth. | Blood | 2010 |
| 20975064 | American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. | J Clin Oncol | 2010 |
| 20974674 | American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. | Blood | 2010 |
| 20194236 | Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. | Ann Intern Med | 2010 |
| 20133898 | Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. | Haematologica | 2010 |
| 19105705 | Anagrelide: 20 years later. | Expert Rev Anticancer Ther | 2009 |
| 19797525 | Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. | Blood | 2009 |
| 19762516 | Anemia management in oncology and hematology. | Oncologist | 2009 |
| 19762512 | Update on erythropoiesis-stimulating agents and clinical trials in oncology. | Oncologist | 2009 |
| 19521323 | The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. | Clin Adv Hematol Oncol | 2009 |
| 18401028 | The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. | Blood | 2008 |
| 18779395 | MPDs: it's all in the family. | Blood | 2008 |
| 18723264 | Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. | Exp Hematol | 2008 |